Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002026 · ClinicalTrials.gov registry record · NA
Treatment and Suppression of Hairy Leukoplakia in ARC Patients With Oral Acyclovir (ACV)
A NA study, sponsored by Glaxo Wellcome.
- Completed
- Registry status
- NA
- Development phase
NCT00002026: Completed NA study, sponsored by Glaxo Wellcome.
NCT00002026 is a NA study that has completed, run by Glaxo Wellcome. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002026, a NA study, has completed, sponsored by Glaxo Wellcome.
- COMPLETED
- Registry status
- NA
- Development phase
Study Summary
To evaluate the efficacy of oral acyclovir for the treatment and suppression of Epstein-Barr virus (EBV) related hairy leukoplakia (HL). To determine the long-term safety of acyclovir in the AIDS-related complex (ARC) patient with HL. To monitor the progression of HIV disease in the HL patient and compare to existing historical control data.
Interventions
- DRUG Acyclovir
Trial Details
| Field | Value |
|---|---|
| Phase | NA |
What the finished NCT00002026 record still lists
NCT00002026 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which Acyclovir is the first listed.
NCT00002026 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002026 about?
NCT00002026 is a clinical study titled "Treatment and Suppression of Hairy Leukoplakia in ARC Patients With Oral Acyclovir (ACV)". To evaluate the efficacy of oral acyclovir for the treatment and suppression of Epstein-Barr virus (EBV) related hairy leukoplakia (HL). To determine the long-term safety of acyclovir in the AIDS-related complex (ARC) patient with HL. To monitor the progression of HIV disease in the HL patient and c...
What is the current status of trial NCT00002026?
This trial is currently completed. It is a NA study.
What interventions are being tested in trial NCT00002026?
The interventions under investigation include: Acyclovir (DRUG).
Who is sponsoring clinical trial NCT00002026?
This trial is sponsored by Glaxo Wellcome, which has 65 total clinical trials registered on ClinicalTrials.gov.